Clinical meaning
the clinician must master advanced heart failure classification, guideline-directed medical therapy (GDMT), and ECG interpretation at a diagnostic level. Understanding the molecular pharmacology and pathophysiological rationale behind each therapeutic intervention enables evidence-based prescribing decisions that directly impact patient survival and quality of life. Heart Failure Classification and Staging requires understanding both the structural progression and functional impact of cardiac disease. The ACC/AHA staging system reflects the irreversible continuum of heart failure: Stage A identifies patients at risk due to hypertension, diabetes, obesity, coronary artery disease, or cardiotoxic drug exposure who have no structural heart disease yet but whose risk factors are initiating subclinical myocardial damage through oxidative stress, chronic inflammation, and neurohormonal activation. Stage B represents structural heart disease without symptoms, where pathological remodeling is occurring at the cellular level through myocyte hypertrophy, interstitial fibrosis from activated cardiac fibroblasts depositing collagen types I and III, and early apoptotic cell loss, but compensatory mechanisms maintain adequate cardiac output at rest. Stage C marks the transition to symptomatic heart failure where compensatory mechanisms have been overwhelmed and the neurohormonal activation (RAAS, sympathetic...